Form D · Other
MCAL Therapeutics Inc.
Park City, UT · CIK 0001812100
Offering snapshot reported Mar 27, 2024 · SEC filing
- Reported sold
- $5.89M Offering amount: $5.89M
- Investors reported
- 29 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 12, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 27, 2024 | Initial | $5,887,549 | No comparison | 29 | SEC filing |
| Jun 4, 2020 | Initial | $449,994 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-508812
Source: Form D, filed Mar 27, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dan Albert | Director |
| Thomas Gadek | Director, Executive |
| Tom Gadek | Director, Executive |
| Tom Mather | Director |
| Christopher J. Murphy | Director |
| Chris J. Murphy | Director |
| Charles O'neill | Director |
| Tanya Shnaydman | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
291 Daly Ave
Park City, UT, 84060
Park City, UT, 84060